The CannaDx™ Sensor & Smartphone App Empowers Users with the Ability to Test and Rate Cannabis Strains
NASA SUPPORTED SCIENCE & TECHNOLOGY POWERS NEW MYDX CONSUMER CANNABIS ANALYZER
Product Photo Attached
SAN DIEGO, July 14, 2015 (GLOBE NEWSWIRE) -- MyDx, Inc. creator of MyDx™ (My Diagnostic), the first battery operated, handheld, chemical analyzer for consumers, has begun the nationwide roll-out of their initial product containing the CannaDx™ sensor and App, designed to help consumers test and find a Cannabis strain that works for them.
The MyDx Analyzer is now being sold online at www.cdxlife.com and via wholesale distribution partners. The MyDx App is available for iOS and Android devices through the Apple App Store and Google Play.
MyDx uses interchangeable sensors to test solids, liquids and gases of interest to reveal their chemical composition. MyDx Started as a crowd funding campaign on Indiegogo and incorporates proprietary "electronic nose" technology formerly used by NASA. Samples "sniffed" by the sensorare sent via Bluetooth to the MyDx App, giving users a chemical profile of their sample and asking them, "How did this make you feel?" or "What did it help you relieve?"
Following the launch of the CannaDx sensor, additional planned products include OrganaDx™ for pesticides in food, AquaDx™ for chemicals in water, and AeroDx™ for pollutants in the air, which would complete the founders' mission to offer consumers a quick, easy and affordable way to test the safety and composition of what they eat, drink and inhale.
"Thanks to the feedback from the 220 Beta customers who were the first to pre-order and test our analyzer in the field, we are excited to officially launch our first product." said Daniel Yazbeck, Chairman and CEO of MyDx. "With our manufacturing capability, strong pre-orders, and distribution pipeline in place, we are now officially shipping units to customers nationwide."
Cannabis contains over 400 different chemicals that can affect feelings and relieve ailments such as stress, anxiety and pain. The CannaDx sensor measures the levels of key chemicals of interest, including Tetrahydrocannabinol (THC), Cannabidiol (CBD), and Terpenes.
"Our vision for this first application is to empower individual consumers to test the broader chemical profile of their cannabis samples and correlate it to how it makes them feel so they can more consistently find a strain that works for them," continued Yazbeck, a former scientist for Pfizer Pharmaceuticals and new product & market developer for Panasonic. "We believe our technology is disruptive, and consumers will benefit from greater accessibility to testing."
About the MxDx™ Analyzer
The company's first product suite includes the MyDx Analyzer, CannaDx Sensor, Disposable Sample Inserts, and the free MyDx App. Together, the solution analyzes and tracks the chemical profiles present and feelings associated with a given cannabis sample. Pricing for the unit, which can accommodate multiple sensors for different applications, is $699.00.
- Real-time measurement of the chemical profile of the plant, including cannabinoids and terpenes
- Handheld, battery operated and fits in your back pocket
- Easy to use (no training required other than operating a smartphone)
- Tracking journal of what you tested and how it made you feel
- Recommendation engine that leverages your data to recommend strains that will work for you
About MyDx, Inc.
MyDx, Inc. (OTCQB: MYDX) is a science and technology company based in San Diego, California whose mission is to help people Trust & VerifyTM what they put into their minds and bodies. The Company has developed MyDx, an affordable portable analyzer that provides real-time chemical analysis and fits in the palm of your hands. MyDx leverages over a decade of established electronic nose technology to measure chemicals of interest and has four sensors being developed in its lab that are compatible with the MyDx Analyzer and App. For more information, please visit www.cdxlife.com.
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov.
A photo accompanying this release is available at: